Phase 2 Stroke Trial, Recruiting NCT06404268 Sponsor: University of Maryland, Baltimore Condition: Stroke
Back to Stroke

Phase 2 Stroke Trial, Recruiting

NCT06404268
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have had their first stroke on one side of the brain (either a bleed or a blockage), starting from 24 hours after being admitted to hospital up to one month after the stroke occurred
  • People who have weakness or paralysis on one side of the body as a result of their stroke
  • People whose muscle strength in the affected limb is very low or absent, based on a standard strength test (scored 0 to 2 out of 5)
  • People aged between 30 and 85 years old
  • People who have ankle problems on the affected side, such as tight calf muscles and/or difficulty lifting the foot upward

Who may not be able to join:

  • People whose medical condition is not currently stable
  • People who have another serious illness at the same time that would prevent them from participating in physical training or exercise
  • People who have no ankle problems, or only very mild ankle problems, on the affected side
  • People with serious heart or circulation problems that would prevent them from doing moderate movement exercises
  • People who have difficulty thinking clearly or understanding and following spoken or written instructions
  • People experiencing severe pain in their legs
  • People whose ankle is severely stiff and stuck in a downward-pointed position (more than 15 degrees, when a doctor or therapist tries to move it upward) (confirm with trial site)
  • People who have pressure sores, a recent surgical wound, or open skin sores or wounds below the knee

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Li-Qun Zhang, University of Maryland

Phone: 410 706-8625

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
1 June 2025
Est. completion
31 December 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Fugl-Meyer Lower Extremity (FMLE)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov